Neuroprotective effects of AAV2-h1L-10 in mouse model of Parkinson's disease

• Autorzy: Joniec L. , Ciesielska A. , Gladka A. , Cudna A. , Zaremba M. , Kurkowska-Jastrzebska L. , Hadaczek P. , Bankiewicz H. , Czlonkowska A. , Czlonkowski A.
• Języki publikacji: EN

Abstrakty

EN

Parkinson’s disease (PD) is a neurodegenerative disorder which is characterized by abnormal loss of nigrostriatal dopamine (DA) neurons, accompanied by DA defi ciency in the striatum. The pathomechanism by which DA neurons degenerate is still unknown, however, there is increasing evidence that is possible immunological mechanisms involvement in the etiopathogenesis of PD. The aim of the present study was to examine the effect of an adeno-associated viral type-2 (AAV2) vector containing human interleukin-10 (hIL-10) gene on dopaminergic system restoration in the murine model of PD induced by by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Male C57BL/6 mice 12 months-old were used in this study. MPTP was injected in four intraperitoneal injections at 1-h intervals. AAV2-hIL-10 vector was bilaterally administered into striatum at 14, 21 or 28 days prior to MPTP intoxication. Animals were sacrifi ced at 7 days following MPTP injection. Striatal DA, DOPAC, HVA concentrations were quantifi ed by HPLC method; tyrosine hydroxylase (TH) mRNA expression was measured by RT-PCR method. MPTP treatment dramatically decreased DA concentration, signifi cantly decreased TH mRNA gene expression. AAV2-hIL-10 exerted a neuroprotective effect upon dopaminergic system (lower decrease in DA concentration). Additionally, viral vector administration prevented depletion of TH mRNA expression induced by MPTP. Our data suggest that AAV2-hIL-10 may play a neuroprotective role in MPTP mouse model of PD.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 3
• Opis fizyczny: p.345

Twórcy

autor

Joniec L.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Ciesielska A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Gladka A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Cudna A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Zaremba M.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Kurkowska-Jastrzebska L.

• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Hadaczek P.

• Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA

autor

Bankiewicz H.

• Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA

autor

Czlonkowska A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Czlonkowski A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland